FTRE

Pre-market Hot Trades in US Stocks

Fortrea is up 8.37% in pre-market trading. Based on recent important news:

1. On January 19, the news of a national biopharmaceutical alliance procurement led by Innovent Biologics in Anhui caused a drop in stock prices of over 10%, but subsequently, Innovent's situation improved, showing potential for a breakout, with a firm revenue target for 2027.

2. On January 20, WuXi AppTec signed a licensing agreement with Abbott covering 69 emerging markets, driving the stock price up.

3. On January 20, WuXi AppTec received approval from the National Medical Products Administration to conduct clinical trials for a new drug, boosting market confidence.

Fox-A is up 7.21% in pre-market trading. According to recent key news:

1. On June 25, Fox Corporation reported third-quarter results that exceeded expectations, with adjusted earnings per share of $1.10, a 27% year-on-year revenue increase, and a 65% surge in advertising revenue, driving the stock price up.

2. On June 26, the overall market rose, and Fox Corporation's stock price followed suit.

3. On June 27, Fox Corporation's stock price continued to benefit from strong performance, showing significant pre-market gains.

Top Gainers in Pre-market Trading of US Stocks

ENDRA Life Sciences is up 183.83% in pre-market trading. Based on recent important news:

1. On May 16, Wall Street set a 12-month target price of $50 for ENDRA Life Sciences, rating it as "Buy," leading to a significant stock price increase.

2. On May 19, the stock price of 3SBio surged 20.01%, enhancing market confidence in the biotechnology sector.

3. On May 21, the Hang Seng Biotechnology Index continued its strong performance, driving related stocks up.

ZyVersa Therapeutics is up 59.05% in pre-market trading. Based on recent important news:

1. On January 19, the stock price dropped over 10% due to the news of a national biopharmaceutical alliance procurement led by Innovent Biologics in Anhui.

2. On January 20, Morgan Stanley released a research report stating that the privatization of Fosun Pharma has limited impact on it.

3. On January 20, the shareholders of UBTECH terminated the concerted action agreement, causing the stock price to drop over 30%.

ProKidney is up 55.02% in pre-market trading. Based on recent important news:

1. On July 8, ProKidney announced the Phase II results of the REGEN-007 trial, showing significant efficacy of Rilparencel in patients with chronic kidney disease and diabetes, with no serious adverse events observed, leading to a substantial stock price increase.

2. On July 8, the company stated that the results of REGEN-007 enhanced confidence in the design of the Phase III PROACT 1 trial, planning to hold a Type B meeting with the FDA, which may accelerate the approval of Rilparencel.

3. On July 8, ProKidney reported that after Rilparencel treatment, the eGFR slope improved by 78% in the first group of patients and by 50% in the second group, further boosting market confidence